Clinical bottom line
Low-dose naltrexone (LDN) is an emerging, putative therapeutic option for patients with small fiber neuropathy (SFN), particularly cryptogenic cases where conventional treatments are limited. Preliminary observational data suggest LDN may reduce neuropathic pain and improve quality of life in this population, but robust randomized controlled trials are lacking. Clinicians should consider LDN as an off-label adjunct in refractory SFN after careful patient selection and counseling about the current evidence gaps and potential side effects.
What the evidence shows
Small fiber neuropathy is characterized by damage to small unmyelinated C fibers and thinly myelinated Aδ fibers, leading to neuropathic pain, dysesthesia, and autonomic symptoms. Conventional management focuses on symptomatic relief with neuropathic pain agents, but many patients experience inadequate response or intolerable side effects.
A recent cohort study by Ahmed Syed et al. (2024) evaluated the use of LDN in patients with cryptogenic SFN. This observational study reported that LDN, administered at doses typically ranging from 1.5 to 4.5 mg daily, was associated with clinically meaningful reductions in neuropathic pain scores and improved patient-reported outcomes over several months of follow-up. The authors hypothesize that LDN’s modulation of microglial activation and neuroinflammation may underlie its analgesic effects in SFN.
LDN’s mechanism involves antagonism of opioid receptors at low doses, paradoxically leading to upregulation of endogenous endorphins and modulation of inflammatory pathways. This mechanism has been explored in other chronic pain conditions, including fibromyalgia and complex regional pain syndrome, with some supportive evidence (Bostick et al., 2019).
While LDN is better studied in other contexts such as autoimmune and inflammatory disorders (Myers et al., 2025), its application in SFN is relatively novel. The Ahmed Syed cohort represents one of the first clinical series focusing on SFN specifically. Notably, the study excluded patients with known causes of SFN such as diabetes or autoimmune disease, focusing on cryptogenic cases where treatment options are limited.
Caveats and uncertainty
The evidence base for LDN in SFN remains preliminary and hypothesis-generating. The Ahmed Syed et al. study is observational, lacks a control group, and has a small sample size, limiting causal inference and generalizability. Placebo effects are a concern given the subjective nature of neuropathic pain assessment.
There are no published randomized controlled trials specifically evaluating LDN in SFN to date. The safety profile of LDN appears favorable, but long-term data in this population are lacking. Potential side effects include vivid dreams, gastrointestinal upset, and transient headache.
Additionally, SFN is a heterogeneous condition with diverse etiologies and pathophysiologies, which may influence response to LDN. Biomarker or phenotypic predictors of response have not been identified. The role of LDN in SFN secondary to systemic diseases such as diabetes or post-viral syndromes remains unclear.
Clinicians should also be aware of the limited regulatory approval and off-label status of LDN for neuropathic pain, requiring informed consent and shared decision-making.
How this may change practice
For primary care clinicians managing patients with cryptogenic SFN who have refractory neuropathic pain despite standard therapies, LDN may represent a promising adjunctive option. Its low cost, oral administration, and relatively benign side effect profile make it an attractive candidate for off-label use in selected patients.
Before initiating LDN, clinicians should confirm the diagnosis of SFN through clinical assessment and, where available, confirmatory testing such as skin biopsy or quantitative sensory testing, referencing established diagnostic criteria (Müller et al., 2013). Patients should be counseled about the limited evidence base, potential benefits, and uncertainties.
LDN initiation should be accompanied by close monitoring of symptom response and adverse effects. Coordination with neurology or pain specialists may be beneficial for complex cases. Further research, including randomized controlled trials, is needed to establish efficacy, optimal dosing, duration, and patient selection criteria.
In summary, LDN is a putative, hypothesis-generating treatment for cryptogenic SFN that warrants cautious consideration and further validation in primary care settings.